Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could you see a lady with recurrent ovarian cancer even think for a second between an arm that is painful to move for a while versus dying from cancer? "No thought give me the shot!" Is what she would say.
I agree. Keytruda was approved with a moderate risk profile. The FDA looks at the risk-benefit ratio of cancer immunotherapy treatments. Chimeric antigen receptor t cell treatments have killed people and they are still highly sought after.
I completely agree, will be worth billions in several years
They own the rights to the first of Knutson's her2 neu epitopes. He also has approx 500K shares so has an interest in the stock price
No, don't think that either. Do you think Wilson will just try to sell TPIV before Phase 2 is complete?
I didn't see anything threatening or vulgar with it. I don't agree with the accusation that we are not accomodating to newbies on this board but I don't feel the comment needs to be removed.
Google videos with Keith Knutson and Glynn Wilson "talking about TapImmune" Also Google "Edith Perez and Mayo Jacksonville TNBC vaccine and TapImmune"
research the new epitopes discovered by Knutson for folate receptor alpha and Her2 neu
I wonder at what price would he sell it all to another company?
The antibody selected is a very vital part of the CAR-T cell design and central to its' efficacy.
Wonder how long Michael French wants to stay independent?
The website has the March 26 Maidstone presentation posted and it says the Triple Negative Breast cancer vaccine starts Phase 2 in 3Q 2015. Mayo Jacksonville listed as lead site and Edith Perez as primary investigator. That's all good news to me. Just 9 months later than expected, but they are coordinating many things with the FDA.
Can't wait to see what the Phase 2 trial plan looks like with Mayo and VGTI working together. Google Edith Perez and what she was saying about our TNBC vaccine in early Feb. The story mentions she collaborated with our SAB chairman Keith Knutson.
I think Marina will be worth a billion market cap in a few years if they don't completely sell the company to a larger company.
MabVax has a unique way to discover fully human monoclonal antibodies and they are working with Heidelberg on antibody drug conjugates. Seattle Genetics is further along obviously but is worth $3 or $4 billion? Oh and MabVax also has rights to 8 cancer vaccines. I see a market cap in the billions in 3-5 years.
Come on get it done! Get moving with the strategy! We should be at $200 million market cap
They need to start Phase 2 to get the stock away from manipulators.
MabVax is severely undervalued. Antibody drug conjugates will be worth billions if they show strong efficacy.
Antibody drug conjugates will be huge for MabVax. The vaccines are just icing on the cake if they show positive phase 2 results.
I do think Glynn mentioned combo solutions with monoclonal antibodies in the recent Biomed Reports interview.
Would like to see them work with monoclonal antibodies on breast and colon cancer. Have the best solution with T cell activation inside the body and fully human mAbs.
Would like to see them work with monoclonal antibodies on breast and colon cancer. Have the best solution with T cell activation inside the body and fully human mAbs.
Get the secondary done already!
Vultures now step in to fund them after TPIV has been manipulated into oblivion. Now I know the game. Can't wait until I am a millionaire and can play the game right. Learned through the school of getting burned by richer, smarter more ruthless people.
Read the latest press release from Feb. 25 especially the third paragraph on IP.
No good reason for the stock to be at 84 cents. Easily manipulated since very thinly traded. No buying interest at moment to support price. I will add more soon and hold for 10 years.
Huge patent estate!
Think we bottomed out? I agree huge potential long term!
New advisor Bonfiglioni will help Glynn unlock value in TPIV.
I thought it was very undervalued at $2.50 last summer. I think it has been manipulated down to a ridiculous level but seems like that is over as it it now rising rapidly. I believe it should be at $5 per share now based on Phase 2 trials starting soon.
They will restart the FAP trial once they raise cash
The combined mAb and vaccine solutions will win in the future and create value for MabVax shareholders.
TapImmune needs to partner the smallpox and TB programs now for cash. Just sell them to establish credibility. We don't have time to work on them anyway.
TapImmune (TPIV) is the company behind this vaccine. Keith Knutson is the chairman of the scientific advisory board for TapImmune.
Google "Money Talk Station and Glynn Wilson' and listen to the recordings from 12-23, 12-30 and 1-6. Much more background info than can get in press releases.
Wish Marina would adapt their technology for immunotherapy!
Would like to see MabVax work with TapImmune and Regen BioPharma on immunotherapy projects.
I'm done following this piece of crap stock. I won't sell until someone stronger that can execute buys the great technology. Our mgmt team never learned how to sell the story to institutional investors.
Look like price manipulation on the Pink Sheets to anyone else?
I do agree with Glynn that TPIV will be worth $1 billion or more in 5 years. Knutson's epitopes will ensure that.
Added more yesterday and will continue as I make more money.